Pharmacology

Bisphosphonates and Gastrointestinal Cancer: Is There a Link?

Preclinical studies have shown that bisphosphonates, one of the treatments for osteoporosis, have antitumor properties, but other studies have sounded a warning about esophageal cancer. To find out whether adverse effects on the gastrointestinal (GI) tract, such as mucosal irritation, could lead to ulceration and possibly cancer, researchers from University Park in Nottingham, United Kingdom, designed a series of nested case-control studies using the 2 largest population databases in the United Kingdom. They matched patients aged ≥ 50 years who had a diagnosis of primary GI cancer with up to 5 controls.


 

Recommended Reading

Oncologist Communication Feedback Improves Patient Trust
AVAHO
A Brighter Prognosis in Nonalcoholic Fatty Liver Disease
AVAHO
Posterior Reversible Encephalopathy Syndrome as a Complication of Chemotherapy
AVAHO
CLEOPATRA Study and MBC
AVAHO
Diabetes May Increase Risk of Cancer Death
AVAHO
Clinical Trial List for Cancer
AVAHO
Burn Scar Carcinoma: Patients With Marjolin's Ulcer
AVAHO
Evaluation of Vitamin D Supplementation in a Veteran Population
AVAHO
Vitamin D Deficiency
AVAHO
Venous Thromboembolism and Weight Changes in Veteran Patients Using Megestrol Acetate as an Appetite Stimulant
AVAHO